With changes in lifestyle and improvements in living standards, the global incidence of obesity and type 2 diabetes is continuously rising, while the market demand for weight loss drugs has also significantly increased, especially with the rise of GLP-1 class drugs, which has driven the development of the entire industry. Currently, commonly available weight loss drugs on the market include Tirzepatide, Semaglutide, Liraglutide, Orlistat, among others. Now, a new member has been added——Orforglipron.
Orforglipron was discovered by Chugai Pharmaceuticals Company in Japan. In 2018, the company licensed Orforglipron to the international pharmaceutical giant Eli Lilly for the development of a new type of small molecule, non-peptide oral GLP-1 receptor agonist. By April 2025, Orforglipron completed its phase three clinical trials. Unlike traditional injectable drugs such as Tirzepatide, Orforglipron is an oral non-peptide small molecule drug, which brings more convenience.
Clinical manifestations:
In clinical manifestations, Orforglipron has shown excellent weight loss and blood sugar-lowering effects, which can exert effective anti-diabetic action by enhancing glucose-dependent insulin secretion and improving energy balance. Phase 1 clinical trials found that Orforglipron has effects similar to GLP-1 and can be used to treat obesity and type 2 diabetes. Phase 2 clinical trial data indicated that during a 36-week trial period, Orforglipron led to a weight reduction of 9.4% to 14.7% in patients. In a 40-week Phase 3 trial, Orforglipron significantly reduced glycated hemoglobin by 1.24% to 1.48% in patients, demonstrating strong blood sugar control capability.
Summary:
Orforglipron is an orally effective glucagon-like peptide-1 (GLP-1) receptor agonist developed by the American company Eli Lilly, which can effectively improve obesity and type 2 diabetes.
Basic Information：
Name: Orforglipron
CAS: 2212020-52-3
Molecular formula: C48H48F2N10O5
Molecular weight: 882.97
Post time: 2025-09-08